Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...

In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Highlights,Commonwealth Equity Services LLC refines its position in Viking Therapeutics Inc.,Company operates within the ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Articles by Jea Yu The weight loss drug sector continues to attract investors. This week, Jea Yu wrote about Viking Therapeutics Inc.'s (NASDAQ: VKTX) potential game-changing GLP-1 offering. Although ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...